Literature DB >> 29666076

Histoplasma meets Crohn's disease: a rare case of new-onset ascites.

Charles Robert Bosshardt1, John Gnann2, Nilesh Lodhia1.   

Abstract

A 53-year-old man with Crohn's disease treated with adalimumab was hospitalised with abdominal pain, fatigue, fever and chills. CT scan of the abdomen showed chronic thickening of the terminal ileum and cecum and new-onset ascites. Further studies revealed weakly positive urine and serum histoplasma antigen. Laparoscopy revealed metastatic caking of the omentum and abdominal wall; peritoneal biopsy demonstrated organisms morphologically consistent with Histoplasma capsulatum No dissemination outside of the peritoneal cavity was evident. The patient completed 2 weeks of liposomal amphotericin B followed by oral itraconazole for 1 year. Adalimumab therapy was held for 10 weeks, then restarted. Presenting symptoms resolved following initiation of antifungal therapy. Follow-up MRI of his abdomen demonstrated resolution of ascites. To our knowledge, this is the first reported case of histoplasmosis presenting as peritonitis in a patient with Crohn's disease receiving antitumour necrosis factor-alpha (TNF-α) therapy. Many clinicians are aware that patients receiving anti-TNF-α therapy are at increased risk for histoplasmosis, but may fail to consider the diagnosis in the absence of lung involvement. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  crohn’s disease; drugs: gastrointestinal system; gastroenterology; infection (gastroenterology); inflammatory bowel disease

Mesh:

Substances:

Year:  2018        PMID: 29666076      PMCID: PMC5905793          DOI: 10.1136/bcr-2017-221572

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

1.  Primary tuberculous peritonitis during infliximab therapy for Crohn's disease.

Authors:  Ulrich Bonse-Geuking; Michael Kraus
Journal:  J Crohns Colitis       Date:  2012-02-27       Impact factor: 9.071

2.  Presentation and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with antitumor necrosis factor alpha therapy: a case series.

Authors:  Jennifer L Dotson; Wallace Crandall; Hayat Mousa; Jonathan R Honegger; Lee Denson; Charles Samson; Dennis Cunningham; Jane Balint; Molly Dienhart; Preeti Jaggi; Ryan Carvalho
Journal:  Inflamm Bowel Dis       Date:  2011-01       Impact factor: 5.325

3.  Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases.

Authors:  Paschalis Vergidis; Robin K Avery; L Joseph Wheat; Jennifer L Dotson; Maha A Assi; Smyrna A Antoun; Kassem A Hamoud; Steven D Burdette; Alison G Freifeld; David S McKinsey; Mary E Money; Thein Myint; David R Andes; Cynthia A Hoey; Daniel A Kaul; Jana K Dickter; David E Liebers; Rachel A Miller; William E Muth; Vidhya Prakash; Frederick T Steiner; Randall C Walker; Chadi A Hage
Journal:  Clin Infect Dis       Date:  2015-04-13       Impact factor: 9.079

4.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Authors:  Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

5.  Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

Authors:  W J Sandborn; S B Hanauer; P Rutgeerts; R N Fedorak; M Lukas; D G MacIntosh; R Panaccione; D Wolf; J D Kent; B Bittle; J Li; P F Pollack
Journal:  Gut       Date:  2007-02-13       Impact factor: 23.059

6.  Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy.

Authors:  Chadi A Hage; Suzanne Bowyer; Stacey E Tarvin; Debra Helper; Martin B Kleiman; L Joseph Wheat
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079

7.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

Authors:  Stephen B Hanauer; William J Sandborn; Paul Rutgeerts; Richard N Fedorak; Milan Lukas; Donald MacIntosh; Remo Panaccione; Douglas Wolf; Paul Pollack
Journal:  Gastroenterology       Date:  2006-02       Impact factor: 22.682

Review 8.  Fungal infections complicating tumor necrosis factor alpha blockade therapy.

Authors:  Sotirios Tsiodras; George Samonis; Dimitrios T Boumpas; Dimitrios P Kontoyiannis
Journal:  Mayo Clin Proc       Date:  2008-02       Impact factor: 7.616

Review 9.  Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites.

Authors:  Lin-Lin Huang; Harry Hua-Xiang Xia; Sen-Lin Zhu
Journal:  J Clin Transl Hepatol       Date:  2014-03-15

Review 10.  Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.

Authors:  Gerd R Burmester; Remo Panaccione; Kenneth B Gordon; Melissa J McIlraith; Ana P M Lacerda
Journal:  Ann Rheum Dis       Date:  2012-05-05       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.